We develop and apply physiologically relevant human organoid systems for disease modeling, therapeutic testing, and mechanistic studies.
_ARR3_GFP%20(1).jpg)
Our protocols deliver markedly lower batch-to-batch variation than competitors, while reaching human-relevant developmental maturity far faster, for predictable, dependable data.
Shown here for our iPSC-derived retinal organoids as a representative example of the platform's reproducibility.
Our retinal organoid model illustrates the level of biological complexity and characterization achieved across our platform. It contains all major retinal cell types organized in their native layered architecture, confirmed by brightfield and immunofluorescence imaging. Every model system below is characterized with the same level of depth and rigor.


.jpg)

Brain organoids are iPSC-derived models that recapitulate key features of human brain development and function. Multiple neural cell types self-organize into tissue-like structures, making it possible to study cellular interactions and region-specific biology in a controlled, human-relevant in vitro system.
Nocteva generates both whole-brain (cerebral) and region-specific organoids, a precise platform to investigate disease mechanisms, characterize cellular dysfunction, and evaluate therapeutic interventions where they matter most.
Day 20 · BF
Day 50 · IF
Day 20 · BF
Day 50 · IF
Day 20 · BF
Day 75 · IFRetinal organoids recapitulate the key features of the human retina, including the presence and organization of all major retinal cell types. Derived from iPSCs, they provide a human-specific platform to study retinal development, disease mechanisms, and therapeutic interventions where animal models and 2D cultures fall short.
Nocteva has optimized retinal organoid generation for robust reproducibility, consistent cellular composition, and low batch-to-batch variability, with standardized differentiation protocols and rigorous quality control.



Nocteva's cardiac platforms span 2D cardiomyocyte monolayers to 3D cardiac organoids — human iPSC-derived models that recapitulate cardiac tissue composition, contractile activity, and electrophysiology for disease modeling and therapeutic evaluation.
Cardiac organoid generation is optimized and standardized for high reproducibility, consistent tissue composition, and robust functional performance.


iPSC-derived cardiomyocytes form spontaneously contracting 2D monolayers — a simple, scalable platform for cardiotoxicity screening and functional assays.


Live imaging captures rhythmic, spontaneous beating in real time — a direct functional readout of cardiac tissue health, drug response, and electrophysiological activity.
Nocteva builds a connected suite of human iPSC-derived neuromuscular models, from neuromuscular, skeletal muscle, and spinal cord organoids to functional spinal motor neurons, providing physiologically relevant platforms to study motor-neuron and muscle biology, disease, and therapeutic response.

.jpg)
Spinal cord organoids reproduce the cellular diversity and organization of the developing human spinal cord, including populations of motor neurons — a platform for studying motor circuits, spinal development, and motor-neuron disease.




iPSC-derived spinal motor neurons form dense, interconnected networks and mature into cholinergic neurons — enabling the study of motor-neuron biology and diseases such as ALS and spinal muscular atrophy.


Lung organoids are iPSC-derived models that recapitulate key features of human airway and alveolar tissue, including epithelial organization and cell-type diversity, providing a human-relevant platform for studying lung development, disease, and therapeutic response.
Nocteva's apical-out lung organoids present the epithelial surface outward, mimicking the in vivo interface bacteria encounter — making them particularly suited for modeling bacterial infection and testing antibiotics.
BF
IF
IFPatient-derived tumor organoids, including high-grade glioma and glioblastoma (GBM), are generated from patient tumor material and preserve the cellular heterogeneity, invasive behavior, and molecular signatures of the original tumor.
Nocteva establishes and characterizes tumor models for mechanistic studies, therapy testing, and biomarker discovery, with matched molecular profiling available through our multi-omics services.
Day 26 · BF
IF